» Articles » PMID: 39139285

Improving the Response to Lenvatinib in Partial Responders Using a Constrained-Disorder-Principle-based Second-generation Artificial Intelligence-therapeutic Regimen: a Proof-of-concept Open-labeled Clinical Trial

Overview
Journal Front Oncol
Specialty Oncology
Date 2024 Aug 14
PMID 39139285
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The main obstacle in treating cancer patients is drug resistance. Lenvatinib treatment poses challenges due to loss of response and the common dose-limiting adverse events (AEs). The Constrained-disorder-principle (CDP)-based second-generation artificial intelligence (AI) systems introduce variability into treatment regimens and offer a potential strategy for enhancing treatment efficacy. This proof-of-concept clinical trial aimed to assess the impact of a personalized algorithm-controlled therapeutic regimen on lenvatinib effectiveness and tolerability.

Methods: A 14-week open-label, non-randomized trial was conducted with five cancer patients receiving lenvatinib-an AI-assisted application tailored to a personalized therapeutic regimen for each patient, which the treating physician approved. The study assessed changes in tumor response through FDG-PET-CT and tumor markers and quality of life via the EORTC QLQ-THY34 questionnaire, AEs, and laboratory evaluations. The app monitored treatment adherence.

Results: At 14 weeks of follow-up, the disease control rate (including the following outcomes: complete response, partial response, stable disease) was 80%. The FDG-PET-CT scan-based RECIST v1.1 and PERCIST criteria showed partial response in 40% of patients and stable disease in an additional 40% of patients. One patient experienced a progressing disease. Of the participants with thyroid cancer, 75% showed a reduction in thyroglobulin levels, and 60% of all the participants showed a decrease in neutrophil-to-lymphocyte ratio during treatment. Improvement in the median social support score among patients utilizing the system supports an ancillary benefit of the intervention. No grade 4 AEs or functional deteriorations were recorded.

Summary: The results of this proof-of-concept open-labeled clinical trial suggest that the CDP-based second-generation AI system-generated personalized therapeutic recommendations may improve the response to lenvatinib with manageable AEs. Prospective controlled studies are needed to determine the efficacy of this approach.

Citing Articles

Inter-organ correlations in inflammation regulation: a novel biological paradigm in a murine model.

Shabat Y, Rotnemer-Golinkin D, Zolotarov L, Ilan Y J Med Life. 2025; 18(1):67-72.

PMID: 40071160 PMC: 11891616. DOI: 10.25122/jml-2024-0246.


The Constrained Disorder Principle Overcomes the Challenges of Methods for Assessing Uncertainty in Biological Systems.

Ilan Y J Pers Med. 2025; 15(1).

PMID: 39852203 PMC: 11767140. DOI: 10.3390/jpm15010010.


The Co-Piloting Model for Using Artificial Intelligence Systems in Medicine: Implementing the Constrained-Disorder-Principle-Based Second-Generation System.

Ilan Y Bioengineering (Basel). 2024; 11(11).

PMID: 39593770 PMC: 11592301. DOI: 10.3390/bioengineering11111111.


Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders.

Sigawi T, Israeli A, Ilan Y Immunotargets Ther. 2024; 13:525-539.

PMID: 39431244 PMC: 11488351. DOI: 10.2147/ITT.S477841.

References
1.
Khoury T, Ilan Y . Platform introducing individually tailored variability in nerve stimulations and dietary regimen to prevent weight regain following weight loss in patients with obesity. Obes Res Clin Pract. 2021; 15(2):114-123. DOI: 10.1016/j.orcp.2021.02.003. View

2.
Ilan Y . Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response. Front Med (Lausanne). 2022; 8:788777. PMC: 8818992. DOI: 10.3389/fmed.2021.788777. View

3.
Hurvitz N, Ilan Y . The Constrained-Disorder Principle Assists in Overcoming Significant Challenges in Digital Health: Moving from "Nice to Have" to Mandatory Systems. Clin Pract. 2023; 13(4):994-1014. PMC: 10453547. DOI: 10.3390/clinpract13040089. View

4.
Ilan Y . The constrained disorder principle defines living organisms and provides a method for correcting disturbed biological systems. Comput Struct Biotechnol J. 2022; 20:6087-6096. PMC: 9668647. DOI: 10.1016/j.csbj.2022.11.015. View

5.
Azmanov H, Ross E, Ilan Y . Establishment of an Individualized Chronotherapy, Autonomic Nervous System, and Variability-Based Dynamic Platform for Overcoming the Loss of Response to Analgesics. Pain Physician. 2021; 24(3):243-252. View